Limits...
Central Administration of Galanin Receptor 1 Agonist Boosted Insulin Sensitivity in Adipose Cells of Diabetic Rats.

Zhang Z, Fang P, He B, Guo L, Runesson J, Langel Ü, Shi M, Zhu Y, Bo P - J Diabetes Res (2016)

Bottom Line: The aim of the study was further to investigate whether central M617, a galanin receptor 1 agonist, can benefit insulin sensitivity.The results showed that central injection of M617 significantly increased plasma adiponectin contents, glucose infusion rates in hyperinsulinemic-euglycemic clamp tests, GLUT4 mRNA expression levels, GLUT4 contents in plasma membranes, and total cell membranes of the adipose cells but reduced the plasma C-reactive protein concentration in nondiabetic and diabetic rats.The ratios of GLUT4 contents were higher in plasma membranes to total cell membranes in both nondiabetic and diabetic M617 groups than each control.

View Article: PubMed Central - PubMed

Affiliation: Department of Endocrinology, Clinical Medical College, Yangzhou University, Yangzhou, Jiangsu 225001, China.

ABSTRACT
Our previous studies testified the beneficial effect of central galanin on insulin sensitivity of type 2 diabetic rats. The aim of the study was further to investigate whether central M617, a galanin receptor 1 agonist, can benefit insulin sensitivity. The effects of intracerebroventricular administration of M617 on insulin sensitivity and insulin signaling were evaluated in adipose tissues of type 2 diabetic rats. The results showed that central injection of M617 significantly increased plasma adiponectin contents, glucose infusion rates in hyperinsulinemic-euglycemic clamp tests, GLUT4 mRNA expression levels, GLUT4 contents in plasma membranes, and total cell membranes of the adipose cells but reduced the plasma C-reactive protein concentration in nondiabetic and diabetic rats. The ratios of GLUT4 contents were higher in plasma membranes to total cell membranes in both nondiabetic and diabetic M617 groups than each control. In addition, the central administration of M617 enhanced the ratios of pAkt/Akt and pAS160/AS160, but not phosphorylative cAMP response element-binding protein (pCREB)/CREB in the adipose cells of nondiabetic and diabetic rats. These results suggest that excitation of central galanin receptor 1 facilitates insulin sensitivity via activation of the Akt/AS160 signaling pathway in the fat cells of type 2 diabetic rats.

No MeSH data available.


Related in: MedlinePlus

The i.c.v. administration of M617 enhanced the glucose infusing rates in hyperinsulinemic-euglycemic clamp tests (n = 8). The glucose infusing rates were higher in diabetic M617 (D-M617) and nondiabetic M617 (N-M617) groups compared with diabetic controls (DC) and nondiabetic controls (NC), respectively. The rates were lower in D-M617 and DC compared with N-M617 and NC, respectively. All data shown are the means ± SEM. △P < 0.05, △△P < 0.01 versus NC; ●●P < 0.01 versus N-M617; ○○P < 0.01 versus DC.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4835658&req=5

fig1: The i.c.v. administration of M617 enhanced the glucose infusing rates in hyperinsulinemic-euglycemic clamp tests (n = 8). The glucose infusing rates were higher in diabetic M617 (D-M617) and nondiabetic M617 (N-M617) groups compared with diabetic controls (DC) and nondiabetic controls (NC), respectively. The rates were lower in D-M617 and DC compared with N-M617 and NC, respectively. All data shown are the means ± SEM. △P < 0.05, △△P < 0.01 versus NC; ●●P < 0.01 versus N-M617; ○○P < 0.01 versus DC.

Mentions: During the clamp tests, the glucose infusion rates were markedly elevated by i.c.v. injection with M617 (F[3,32] = 90.1, P < 0.0001). Figure 1 showed that the infusion rate in the diabetic M617 group was increased by 30.2% (P < 0.01) compared with diabetic controls but reduced by 27.1% (P < 0.01) compared with the nondiabetic M617 group. Compared with nondiabetic controls, the rate was increased by 8.8% (P < 0.05) in the nondiabetic M617 group but attenuated by 39.1% (P < 0.01) in the diabetic control group.


Central Administration of Galanin Receptor 1 Agonist Boosted Insulin Sensitivity in Adipose Cells of Diabetic Rats.

Zhang Z, Fang P, He B, Guo L, Runesson J, Langel Ü, Shi M, Zhu Y, Bo P - J Diabetes Res (2016)

The i.c.v. administration of M617 enhanced the glucose infusing rates in hyperinsulinemic-euglycemic clamp tests (n = 8). The glucose infusing rates were higher in diabetic M617 (D-M617) and nondiabetic M617 (N-M617) groups compared with diabetic controls (DC) and nondiabetic controls (NC), respectively. The rates were lower in D-M617 and DC compared with N-M617 and NC, respectively. All data shown are the means ± SEM. △P < 0.05, △△P < 0.01 versus NC; ●●P < 0.01 versus N-M617; ○○P < 0.01 versus DC.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4835658&req=5

fig1: The i.c.v. administration of M617 enhanced the glucose infusing rates in hyperinsulinemic-euglycemic clamp tests (n = 8). The glucose infusing rates were higher in diabetic M617 (D-M617) and nondiabetic M617 (N-M617) groups compared with diabetic controls (DC) and nondiabetic controls (NC), respectively. The rates were lower in D-M617 and DC compared with N-M617 and NC, respectively. All data shown are the means ± SEM. △P < 0.05, △△P < 0.01 versus NC; ●●P < 0.01 versus N-M617; ○○P < 0.01 versus DC.
Mentions: During the clamp tests, the glucose infusion rates were markedly elevated by i.c.v. injection with M617 (F[3,32] = 90.1, P < 0.0001). Figure 1 showed that the infusion rate in the diabetic M617 group was increased by 30.2% (P < 0.01) compared with diabetic controls but reduced by 27.1% (P < 0.01) compared with the nondiabetic M617 group. Compared with nondiabetic controls, the rate was increased by 8.8% (P < 0.05) in the nondiabetic M617 group but attenuated by 39.1% (P < 0.01) in the diabetic control group.

Bottom Line: The aim of the study was further to investigate whether central M617, a galanin receptor 1 agonist, can benefit insulin sensitivity.The results showed that central injection of M617 significantly increased plasma adiponectin contents, glucose infusion rates in hyperinsulinemic-euglycemic clamp tests, GLUT4 mRNA expression levels, GLUT4 contents in plasma membranes, and total cell membranes of the adipose cells but reduced the plasma C-reactive protein concentration in nondiabetic and diabetic rats.The ratios of GLUT4 contents were higher in plasma membranes to total cell membranes in both nondiabetic and diabetic M617 groups than each control.

View Article: PubMed Central - PubMed

Affiliation: Department of Endocrinology, Clinical Medical College, Yangzhou University, Yangzhou, Jiangsu 225001, China.

ABSTRACT
Our previous studies testified the beneficial effect of central galanin on insulin sensitivity of type 2 diabetic rats. The aim of the study was further to investigate whether central M617, a galanin receptor 1 agonist, can benefit insulin sensitivity. The effects of intracerebroventricular administration of M617 on insulin sensitivity and insulin signaling were evaluated in adipose tissues of type 2 diabetic rats. The results showed that central injection of M617 significantly increased plasma adiponectin contents, glucose infusion rates in hyperinsulinemic-euglycemic clamp tests, GLUT4 mRNA expression levels, GLUT4 contents in plasma membranes, and total cell membranes of the adipose cells but reduced the plasma C-reactive protein concentration in nondiabetic and diabetic rats. The ratios of GLUT4 contents were higher in plasma membranes to total cell membranes in both nondiabetic and diabetic M617 groups than each control. In addition, the central administration of M617 enhanced the ratios of pAkt/Akt and pAS160/AS160, but not phosphorylative cAMP response element-binding protein (pCREB)/CREB in the adipose cells of nondiabetic and diabetic rats. These results suggest that excitation of central galanin receptor 1 facilitates insulin sensitivity via activation of the Akt/AS160 signaling pathway in the fat cells of type 2 diabetic rats.

No MeSH data available.


Related in: MedlinePlus